[go: up one dir, main page]

NO882560D0 - Midler for aa oeke transdermal stroemning av farmasoeytiske stoffer. - Google Patents

Midler for aa oeke transdermal stroemning av farmasoeytiske stoffer.

Info

Publication number
NO882560D0
NO882560D0 NO882560A NO882560A NO882560D0 NO 882560 D0 NO882560 D0 NO 882560D0 NO 882560 A NO882560 A NO 882560A NO 882560 A NO882560 A NO 882560A NO 882560 D0 NO882560 D0 NO 882560D0
Authority
NO
Norway
Prior art keywords
week
pharmaceutical substances
transdermal flow
transdermal
flow
Prior art date
Application number
NO882560A
Other languages
English (en)
Other versions
NO882560L (no
Inventor
John Michael Pawelchak
James Ronald Lawter
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO882560D0 publication Critical patent/NO882560D0/no
Publication of NO882560L publication Critical patent/NO882560L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
NO882560A 1987-06-12 1988-06-10 Midler for aa oeke transdermal stroemning av farmasoeytiske stoffer. NO882560L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/061,934 US5001139A (en) 1987-06-12 1987-06-12 Enchancers for the transdermal flux of nivadipine

Publications (2)

Publication Number Publication Date
NO882560D0 true NO882560D0 (no) 1988-06-10
NO882560L NO882560L (no) 1988-12-13

Family

ID=22039100

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882560A NO882560L (no) 1987-06-12 1988-06-10 Midler for aa oeke transdermal stroemning av farmasoeytiske stoffer.

Country Status (13)

Country Link
US (1) US5001139A (no)
EP (1) EP0321636A3 (no)
JP (1) JPS6413023A (no)
KR (1) KR890000091A (no)
AU (1) AU614523B2 (no)
CA (1) CA1305419C (no)
DK (1) DK316988A (no)
FI (1) FI882791L (no)
IL (1) IL86335A0 (no)
NO (1) NO882560L (no)
NZ (1) NZ224890A (no)
PT (1) PT87703A (no)
ZA (1) ZA884185B (no)

Families Citing this family (408)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4941457A (en) * 1989-08-17 1990-07-17 Olympus Optical Co., Ltd. Endoscope using an optical guide twisted on the tip side to have the visual field direction and curvature axis coincide with each other
IT1243745B (it) * 1990-10-17 1994-06-21 Vectorpharma Int Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione.
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US5990179A (en) * 1995-04-28 1999-11-23 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US5985316A (en) * 1995-04-28 1999-11-16 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
RU2128041C1 (ru) * 1998-08-28 1999-03-27 Общество с ограниченной ответственностью "Научно-производственная компания "АСКОНТ+" Бактерицидно-акарицидная мазь для лечения болезней кожи
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
HK1048250A1 (zh) 2000-02-18 2003-03-28 Cv Therapeutics, Inc. 在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US6919327B2 (en) * 2000-11-17 2005-07-19 Pharmacyclics, Inc. Texaphyrin coordination compounds and uses thereof
AU2002239508B9 (en) 2000-12-07 2005-09-08 Gilead Palo Alto, Inc. Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
HU229504B1 (hu) 2001-11-09 2014-01-28 Gilead Sciences A2B-adenozinreceptor-antagonisták
EP2412716A1 (en) 2002-02-19 2012-02-01 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2003099281A2 (en) 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
KR20050026546A (ko) * 2002-07-29 2005-03-15 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 수용체 작용제를 이용한 심근 관류 조영
WO2004069818A1 (en) 2003-01-17 2004-08-19 Cv Therapeutics Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
ES2334029T3 (es) * 2003-05-15 2010-03-04 Roskamp Research Llc Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis.
EP1682537B1 (en) * 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
RU2391103C2 (ru) 2004-10-15 2010-06-10 Си Ви Терапьютикс, Инк. Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
WO2006044856A2 (en) * 2004-10-20 2006-04-27 Cv Therapeuitics, Inc. Use of a2a adenosine receptor agonists
CA2587406A1 (en) * 2004-11-16 2006-05-26 Limerick Neurosciences, Inc. Methods and compositions for treating pain
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
US7670849B2 (en) * 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
CN101198608B (zh) * 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
US7423045B2 (en) * 2005-06-28 2008-09-09 Cv Therapeutics, Inc. ABCA1 elevating compounds
US20070072838A1 (en) * 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
KR101494125B1 (ko) * 2006-02-03 2015-02-16 길리애드 사이언시즈, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
US20070219174A1 (en) * 2006-03-15 2007-09-20 Pharmacyclics, Inc. Methods of treating cancer using hypofractionated radiation and texaphyrins
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
CA2653056A1 (en) 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2662278C (en) * 2006-09-01 2011-11-22 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US7893066B2 (en) * 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CA2665476A1 (en) * 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
KR101122469B1 (ko) 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
US7662819B2 (en) * 2007-04-09 2010-02-16 Gilead Palo Alto, Inc. Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
GB2463833B (en) * 2007-06-26 2012-02-08 Parkinson S Inst Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
DK2214666T3 (da) * 2007-10-05 2014-01-27 Alzheimer S Inst Of America Inc Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2240451B1 (en) 2008-01-04 2017-08-09 Intellikine, LLC Isoquinolinone derivatives substituted with a purine useful as PI3K inhibitors
CN101983062A (zh) * 2008-02-07 2011-03-02 吉利德帕洛阿尔托股份有限公司 提高abca-1的化合物及其用途
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009137201A1 (en) * 2008-04-04 2009-11-12 Cv Therapeutics, Inc. Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
CN102056485A (zh) * 2008-04-15 2011-05-11 萨可德公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010006086A2 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
EP2344447B1 (en) * 2008-10-08 2016-06-08 Xgene Pharmaceutical Inc Gaba conjugates and methods of use thereof
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010045374A1 (en) * 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010056527A2 (en) 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010056919A2 (en) * 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
CA2761771A1 (en) * 2009-05-14 2010-11-18 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
LT2464645T (lt) 2009-07-27 2017-10-25 Gilead Sciences, Inc. Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai
US20110039799A1 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
US9562056B2 (en) 2010-03-11 2017-02-07 Gilead Connecticut, Inc. Imidazopyridines Syk inhibitors
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
AU2011271510A1 (en) 2010-06-30 2013-01-10 Gilead Sciences, Inc. Use of A2B adenosine receptor antagonists for treating pulmonary hypertension
CN102985418B (zh) 2010-07-02 2015-09-09 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012018387A2 (en) 2010-08-02 2012-02-09 Population Diagnotics, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
PH12013501427B1 (en) 2011-01-07 2019-02-13 Allergan Inc Melanin modification compositions and methods of use
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
PT2683244T (pt) 2011-03-08 2017-05-08 3-V Biosciences Inc Moduladores heterocíclicos de síntese de lipídios
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
NO3175985T3 (no) 2011-07-01 2018-04-28
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
TWI468403B (zh) 2011-08-30 2015-01-11 Gilead Sciences Inc 用於治療成癮之ａｌｄｈ－２抑制劑
JP2014531454A (ja) 2011-09-21 2014-11-27 ギリアード サイエンシーズ， インコーポレイテッド グルカゴン分泌を減少させるナトリウムチャネルブロッカー
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
DK2766483T3 (da) 2011-10-10 2022-04-19 Hospital For Sick Children Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK2773779T3 (da) 2011-11-04 2020-11-23 Population Bio Inc Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande
WO2013120018A1 (en) 2012-02-09 2013-08-15 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
WO2013126617A1 (en) 2012-02-22 2013-08-29 The Regents Of The University Of Colorado, A Body Corporate Bouvardin derivatives and therapeutic uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969588B2 (en) 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
CA2922005A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
NZ708870A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
JP6125663B2 (ja) 2012-12-21 2017-05-10 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤としての置換ピリミジンアミノアルキル−キナゾロン
EP2934540B1 (en) 2012-12-24 2023-08-02 Neurogastrx, Inc. Methods for treating gi tract disorders
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
MX373584B (es) 2013-05-30 2020-05-05 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de la isoforma pi3 cinasa.
HK1223911A1 (zh) 2013-06-14 2017-08-11 Gilead Sciences, Inc. 磷脂醯肌醇3-激酶抑制剂
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
EP3363800A1 (en) 2013-10-03 2018-08-22 Kura Oncology, Inc. Heterocyclic inhibitors of erk and methods of use
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6262363B2 (ja) 2013-11-26 2018-01-17 ギリアード サイエンシーズ， インコーポレイテッド ブロモドメイン阻害剤としてのキノリン誘導体
EA201690608A1 (ru) 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
CA2931431A1 (en) 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
SG11201604457XA (en) 2013-12-19 2016-07-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
JP6568541B2 (ja) 2013-12-23 2019-08-28 ギリアド ファーマセット エルエルシー 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
TW201613908A (en) 2014-02-13 2016-04-16 Gilead Sciences Inc Solid forms of an ion channel modulator
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2015175845A1 (en) 2014-05-15 2015-11-19 Peloton Therapeutics, Inc. Benzimidazole derivatives and uses thereof
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2015191754A2 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
KR102628356B1 (ko) 2014-06-19 2024-01-24 다케다 야쿠힌 고교 가부시키가이샤 키나제 저해를 위한 헤테로아릴 화합물
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
JP6310144B2 (ja) 2014-07-14 2018-04-18 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための組み合わせ
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
TW201609099A (zh) 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
CN106715419A (zh) 2014-09-26 2017-05-24 吉利德科学公司 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
CN111888368B (zh) 2014-10-21 2024-02-02 武田药品工业株式会社 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
EP3250258A4 (en) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Drug delivery methods and systems
KR101994596B1 (ko) 2015-01-28 2019-06-28 주식회사 제네리스코리아 신경정신계 장애의 치료를 위한 조성물 및 방법
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
JP6758314B2 (ja) 2015-03-19 2020-09-23 サギメット バイオサイエンシーズ インコーポレイテッド 脂質合成の複素環式調節因子
SI3191470T1 (sl) 2015-07-06 2019-04-30 Gilead Sciences, Inc. Modulatorji COT in postopki njihove uporabe
EP3319938B1 (en) 2015-07-10 2022-04-06 University of Maryland, Baltimore Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
US10590100B2 (en) 2015-11-11 2020-03-17 Ambient Photonics, Inc. Benzofuran derivatives for the treatment of CNS and other disorders
EP3394044A1 (en) 2015-12-17 2018-10-31 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
US20190008869A1 (en) 2016-01-13 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of an Antifolate and a BTK Inhibitor
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017218802A1 (en) 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
AU2017281222B2 (en) 2016-06-23 2022-06-16 The Usa As Represented By The Department Of Veterans Affairs; Dept. Of Veterans Affairs Office Of General Counsel - Pag Iv (024) Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
EP3478674B1 (en) 2016-06-30 2020-05-13 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
CA3036384A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
WO2018055577A1 (en) 2016-09-23 2018-03-29 Synthena Ag Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018075601A1 (en) 2016-10-18 2018-04-26 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
EP3548033B1 (en) 2016-11-28 2024-04-10 Praxis Precision Medicines, Inc. Compounds and their methods of use
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP3601326A4 (en) 2017-03-20 2020-12-16 The Broad Institute, Inc. COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
EP3621945B1 (en) 2017-05-09 2025-12-10 Ambient Photonics, Inc. Stilbene derivatives for the treatment of cns and other disorders
EP4403171A3 (en) 2017-06-19 2024-09-11 University of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same
EP3665179B1 (en) 2017-08-09 2021-06-09 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
KR102891807B1 (ko) 2017-08-22 2025-12-01 길리애드 사이언시즈, 인코포레이티드 치료 헤테로시클릭 화합물
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
US11752146B2 (en) 2017-09-28 2023-09-12 Medicon Pharmaceuticals, Inc. Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
JP7328218B2 (ja) 2017-10-26 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
EP3710599B1 (en) 2017-11-13 2024-07-17 Gilead Sciences, Inc. Method for staging liver fibrosis in nash patients
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
JP7038843B2 (ja) 2018-02-16 2022-03-18 ギリアード サイエンシーズ， インコーポレイテッド Ｒｅｔｒｏｖｉｒｉｄａｅウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体
RU2020132293A (ru) 2018-03-02 2022-04-04 Орегон Хэлт Энд Сайенс Юниверсити Амидные пролекарства низкомолекулярных модуляторов ядерных рецепторов
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
DK3765461T3 (da) 2018-03-14 2023-11-20 Prelude Therapeutics Inc Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere
WO2019196619A1 (zh) 2018-04-08 2019-10-17 威尚（上海）生物医药有限公司 喹唑啉衍生物盐型晶型及制备方法和应用
EP3778589B1 (en) 2018-04-09 2022-05-11 Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
CA3099775A1 (en) 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
AU2019278814B2 (en) 2018-05-30 2025-12-18 Praxis Precision Medicines, Inc. Ion channel modulators
CA3103987C (en) 2018-07-06 2023-08-01 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
KR20230141905A (ko) 2018-07-16 2023-10-10 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
FI4177356T3 (fi) 2018-08-08 2024-08-07 Pml Screening Llc Menetelmiä virustaudin kehittymisriskin arviointiin geenitestillä
AU2019326265B2 (en) 2018-08-20 2025-07-24 Maggie's Pearl, Llc Methods for treating congenital disorders of glycosylation
US20210330646A1 (en) 2018-08-27 2021-10-28 Spinogenix, Inc. Fascin binding compounds for spinogenesis
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
BR112021008796A2 (pt) 2018-11-09 2021-08-03 Prelude Therapeutics, Incorporated derivados de espiro-sulfonamida como inibidores de proteína de leucemia-1 de células mieloides (mcl-1)
MA54245A (fr) 2018-11-16 2022-02-23 Morningside Venture Investments Ltd Système d'administration transdermique de médicaments à régulation thermique
MA54231B1 (fr) 2018-11-19 2021-12-31 Global Blood Therapeutics Inc Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
WO2020118194A1 (en) 2018-12-07 2020-06-11 University Of Maryland, Baltimore NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020123850A1 (en) 2018-12-13 2020-06-18 Global Blood Therapeutics, Inc. Ferroportin inhibitors and methods of use
WO2020123994A1 (en) 2018-12-14 2020-06-18 Prelude Therapeutics, Incorporated 2-((5-(phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-3-(phenyl)propanoic acid derivatives and related compounds as mcl-1 enzyme inhibitors for treating cancer
RS67123B1 (sr) 2019-01-31 2025-09-30 Spinogenix Inc Čvrsti oblici promotera spinogeneze
US20220133894A1 (en) 2019-02-06 2022-05-05 Oregon Health & Science University Bisphosphonate-linked compounds
US20220160713A1 (en) 2019-02-13 2022-05-26 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
EP3931186A1 (en) 2019-02-25 2022-01-05 CHDI Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
BR112021017831A2 (pt) 2019-03-11 2021-11-30 Collaborative Medicinal Dev Llc Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
TW202544011A (zh) 2019-03-22 2025-11-16 美商基利科學股份有限公司 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
WO2020206299A1 (en) 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
MX2021013421A (es) 2019-05-03 2022-02-11 Praxis Prec Medicines Inc Inhibidores de kcnt1 y metodos de uso.
EP4446314A3 (en) 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
MX2022000492A (es) 2019-07-11 2022-07-04 Praxis Prec Medicines Inc Formulaciones de moduladores de canal de calcio tipo t y metodos de uso de estos.
US12414953B2 (en) 2019-09-18 2025-09-16 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US12371428B2 (en) 2019-09-26 2025-07-29 Exelixis, Inc. Pyridone compounds and methods of use
KR20220119624A (ko) 2019-11-26 2022-08-30 프락시스 프리시젼 메디신즈, 인크. 이온 채널 조절제
WO2021108544A1 (en) 2019-11-26 2021-06-03 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
EP4065114B1 (en) 2019-11-27 2025-11-05 Praxis Precision Medicines, Inc. Method for making relutrigine/prax-562
JP2023503962A (ja) 2019-11-29 2023-02-01 オートバーン セラピューティクス，インク． 新規な甲状腺ホルモン模倣物
WO2021155253A1 (en) 2020-01-31 2021-08-05 Atomwise Inc. Anat inhibitors and methods of use thereof
WO2021173591A1 (en) 2020-02-24 2021-09-02 Exelixis, Inc. Compounds and methods of use
JP7453399B2 (ja) 2020-02-24 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ感染症を治療するための四環式化合物及びその使用
US20230167102A1 (en) 2020-02-28 2023-06-01 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
JP2023520650A (ja) 2020-03-30 2023-05-18 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
BR112022019423A2 (pt) 2020-03-31 2022-12-06 Global Blood Therapeutics Inc Moduladores de hemoglobina
EP4126876A1 (en) 2020-04-01 2023-02-08 Global Blood Therapeutics, Inc. Pyrrolidine-pyrazoles as pyruvate kinase activators
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
PL4126862T3 (pl) 2020-04-02 2025-09-08 Gilead Sciences, Inc. Sposób wytwarzania związku będącego inhibitorem cot
US20230212191A1 (en) 2020-04-16 2023-07-06 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
EP4142732A1 (en) 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
EP4143197A1 (en) 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
BR112022021806A2 (pt) 2020-04-28 2022-12-13 Global Blood Therapeutics Inc Cicloalquilpirimidinas como inibidores de ferroportina
JP2023526235A (ja) 2020-05-13 2023-06-21 プレリュード・セラピューティクス・インコーポレイテッド 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体
AU2021289730A1 (en) 2020-06-09 2023-01-19 Prelude Therapeutics, Incorporated BRM targeting compounds and associated methods of use
WO2021257851A1 (en) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
US20230278984A1 (en) 2020-08-03 2023-09-07 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
US20240011030A1 (en) 2020-08-10 2024-01-11 Novartis Ag Treatments for retinal degenerative diseases
MX2023003264A (es) 2020-09-21 2023-06-06 Prelude Therapeutics Inc Inhibidores de cdk y su uso como productos fármaceuticos.
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
WO2022069701A1 (en) 2020-10-01 2022-04-07 Nogra Pharma Limited Methods of treating pulmonary fibrosis
CA3198715A1 (en) 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
US12448389B2 (en) 2020-11-06 2025-10-21 Prelude Therapeutics Incorporated BRM targeting compounds and associated methods of use
KR20230122096A (ko) 2020-12-18 2023-08-22 프렐루드 테라퓨틱스, 인코포레이티드 Cdk 억제제 및 약제로서의 이의 용도
WO2022140326A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Substituted indole compounds
US20250002471A1 (en) 2020-12-22 2025-01-02 Gilead Sciences, Inc. 6-substituted indole compounds
AU2021405620A1 (en) 2020-12-23 2023-06-29 Actelion Pharmaceuticals Ltd Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
CA3205986A1 (en) 2020-12-30 2022-07-07 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
PL4196479T3 (pl) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Podstawione związki pirydotriazynowe i ich zastosowania
US11566030B2 (en) 2021-02-08 2023-01-31 Global Blood Therapeutics, Inc. Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
AU2022219934B2 (en) 2021-02-09 2024-11-07 Gilead Sciences, Inc. Thienopyrrole compounds
CA3211063A1 (en) 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
US11851424B2 (en) 2021-05-14 2023-12-26 Global Blood Therapeutics, Inc. Solid forms of a modulator of hemoglobin
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
US20240316022A1 (en) 2021-06-30 2024-09-26 Tyra Biosciences, Inc. Indazole compounds
US20240336565A1 (en) 2021-07-02 2024-10-10 Acer Therapeutics, Inc. Solid forms of osanetant
WO2023287787A1 (en) 2021-07-13 2023-01-19 Prelude Therapeutics, Incorporated Brm targeting compounds and associated methods of use
TW202313053A (zh) 2021-07-30 2023-04-01 瑞士商艾克泰聯製藥有限公司 吡唑并嘧啶及其作為ｐｄｇｆｒ抑制劑之用途
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
TWI849499B (zh) 2021-09-10 2024-07-21 美商基利科學股份有限公司 噻吩并吡咯化合物
WO2023056441A1 (en) 2021-09-30 2023-04-06 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
US20240408107A1 (en) 2021-10-06 2024-12-12 Global Blood Therapeutics, Inc. Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
CN118696049A (zh) 2021-11-23 2024-09-24 基因泰克公司 胆固醇生物合成的螺环双环调节剂及其用于促进髓鞘再生的用途
EP4436975A1 (en) 2021-11-23 2024-10-02 Genentech, Inc. Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
WO2023097234A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
CN118369316A (zh) 2021-12-03 2024-07-19 吉利德科学公司 Hiv病毒感染的治疗性化合物
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
AU2022408097A1 (en) 2021-12-10 2024-05-30 Global Blood Therapeutics, Inc. Methods of administering a modulator of hemoglobin
WO2023141571A1 (en) 2022-01-21 2023-07-27 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
JP2025504963A (ja) 2022-01-25 2025-02-19 エビア・セラピューティクス・インコーポレイテッド Ａｍｐｋアゴニスト及びその使用方法
WO2023147134A2 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Methods for treating patients having low estrogen with nk3 antagonists
WO2023147135A1 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Nk receptor antagonists for treatment of prostate cancer
US20230257394A1 (en) 2022-02-03 2023-08-17 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
WO2023172957A1 (en) 2022-03-09 2023-09-14 Prelude Therapeutics, Incorporated Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals
IL315671A (en) 2022-03-23 2024-11-01 Prelude Therapeutics Inc Polymorphic compounds and their uses
WO2023192416A1 (en) 2022-03-29 2023-10-05 Prelude Therapeutics, Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
EP4499611A1 (en) 2022-03-31 2025-02-05 Rarefied Biosciences, Inc. Malt1 modulators and uses thereof
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
IL316386A (en) 2022-05-02 2024-12-01 Esperion Therapeutics Inc Macrocyclic tracking of ATP citrate lyase
US20230365576A1 (en) 2022-05-10 2023-11-16 Prelude Therapeutics Incorporated BRM Targeting Compounds And Associated Methods Of Use
JP2025517423A (ja) 2022-05-20 2025-06-05 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルスインドリニル化合物及びその使用
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
US20230399299A1 (en) 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
JP2025525339A (ja) 2022-06-16 2025-08-05 プレリュード・セラピューティクス・インコーポレイテッド ビキチンリガーゼ結合部分を有するｋａｔ６標的化合物
WO2023247593A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors
WO2023247595A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors
WO2023247590A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors
WO2023247596A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
EP4547670A1 (en) 2022-06-29 2025-05-07 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
CN119731165A (zh) 2022-06-29 2025-03-28 泰拉生物科学公司 吲唑化合物
CA3261875A1 (en) 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR
EP4554943A1 (en) 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
EP4554624A1 (en) 2022-07-15 2025-05-21 Pheon Therapeutics Ltd Antibody-drug conjugates
AU2023306990A1 (en) 2022-07-15 2025-01-09 Celloram Inc. Celastrol derivatives
TW202410893A (zh) 2022-08-31 2024-03-16 日商大塚製藥股份有限公司 用於治療t細胞淋巴瘤之結合治療
WO2024077216A1 (en) 2022-10-06 2024-04-11 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
KR20250113414A (ko) 2022-10-28 2025-07-25 베이스캠프 바이오 인코포레이티드 소마토스타틴 수용체 2 작용제 및 이의 용도
WO2024104968A1 (en) 2022-11-14 2024-05-23 Actelion Pharmaceuticals Ltd Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors
AU2023382631A1 (en) 2022-11-15 2025-05-29 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
WO2024211346A1 (en) 2023-04-03 2024-10-10 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
US20240352029A1 (en) 2023-04-14 2024-10-24 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
WO2024220708A1 (en) 2023-04-19 2024-10-24 Gandeeva Therapeutics, Inc. Raf-mek protein complex modulators and methods of use thereof
AU2024283382A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Anti-hiv compounds
WO2024249573A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
WO2024256964A1 (en) 2023-06-13 2024-12-19 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease
US20250051309A1 (en) 2023-06-29 2025-02-13 Gilead Sciences, Inc. Mk2 inhibitors and methods of making and using the same
WO2025014963A1 (en) 2023-07-10 2025-01-16 Gandeeva Therapeutics, Inc. Inhibitors of p97 protein and methods of use
US20250059175A1 (en) 2023-08-15 2025-02-20 Prelude Therapeutics Incorporated Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals
WO2025049495A1 (en) 2023-08-28 2025-03-06 Genentech, Inc. Tertiary pyridyl amine modulators of cholesterol biosynthesis and their use for promoting remylination
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080879A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202535853A (zh) 2023-11-01 2025-09-16 美商伊斯比瑞恩治療公司 Atp檸檬酸鹽裂解酶之巨環抑制劑
WO2025101942A1 (en) 2023-11-10 2025-05-15 Prelude Therapeutics Incorporated Kat6 targeting compounds
TW202540079A (zh) 2023-11-17 2025-10-16 美商基利科學股份有限公司 抗病毒吲哚啉基化合物及其用途
WO2025104687A1 (en) 2023-11-17 2025-05-22 Gilead Sciences, Inc. Solid forms of a hsv helicase primase inhibitor
TW202535368A (zh) 2023-12-15 2025-09-16 美商泰拉生物科學公司 吲唑化合物
WO2025184459A1 (en) 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
WO2025194405A1 (en) 2024-03-21 2025-09-25 Prelude Therapeutics Incorporated Polymorphic smarca inhibitors and uses thereof
WO2025212814A1 (en) 2024-04-03 2025-10-09 Gilead Sciences, Inc. Anti-hiv compounds
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity
WO2025240835A2 (en) 2024-05-17 2025-11-20 Prelude Therapeutics Incorporated Jak2 inhibitors and their use as pharmaceuticals
CZ2024224A3 (cs) 2024-05-30 2025-12-10 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. 1H-Pyrazolo[3,4-d]pyrimidinové ribonukleosidy s protinádorovou aktivitou pro terapeutické použití
WO2026015548A1 (en) 2024-07-08 2026-01-15 Convelo Therapeutics, Inc. Cyp51 inhibitors and method of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
US4284634A (en) * 1975-07-02 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, and pharmaceutical method of the same
JPS58177916A (ja) * 1982-04-13 1983-10-18 Kowa Co 外用剤
JPS5923673A (ja) * 1982-07-30 1984-02-07 Toshiba Corp 映像ハ−フト−ン回路
JPS5939827A (ja) * 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
JPS59175415A (ja) * 1983-03-25 1984-10-04 Nitto Electric Ind Co Ltd 医薬製剤
JPS6016917A (ja) * 1983-07-08 1985-01-28 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンまたはニフエジピンの軟膏剤
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
DE3447170A1 (de) * 1984-12-22 1986-07-03 Bayer Ag, 5090 Leverkusen Mischung unterschiedlicher dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
FI882791A7 (fi) 1988-12-13
FI882791A0 (fi) 1988-06-10
KR890000091A (ko) 1989-03-11
FI882791L (fi) 1988-12-13
ZA884185B (en) 1989-03-29
IL86335A0 (en) 1988-11-15
PT87703A (pt) 1989-05-31
NZ224890A (en) 1992-06-25
EP0321636A3 (en) 1989-09-27
AU1760988A (en) 1988-12-15
US5001139A (en) 1991-03-19
JPS6413023A (en) 1989-01-17
DK316988D0 (da) 1988-06-10
AU614523B2 (en) 1991-09-05
NO882560L (no) 1988-12-13
DK316988A (da) 1988-12-13
EP0321636A2 (en) 1989-06-28
CA1305419C (en) 1992-07-21

Similar Documents

Publication Publication Date Title
NO882560D0 (no) Midler for aa oeke transdermal stroemning av farmasoeytiske stoffer.
DK546886A (da) Farmaceutisk praeparat til reguleret frigoerelse af aktive stoffer
DK457288D0 (da) Kapsel til farmaceutisk virksomme stoffer
DK215987A (da) Farmaceutiske praeparater af syrelabile stoffer tiloral indgift
NO874873D0 (no) Innretning for autoadministrering av fysiologisk aktive stoffer.
DE3689974D1 (de) Arzneimittel zur Behandlung von Emesis.
NO865202L (no) Tyggbart materiale for utlevering av aktive substanser.
FI813349A7 (fi) 1-Karboksialkanoyyli-indoliini-2- karboksyylihappoja, menetelmiä niiden valmistamiseksi, näitä yhdisteitsisältäviä farmaseuttisia valmisteita ja niiden terapeuttinen käyttö.
FI881579A7 (fi) Syövänvastainen terapia ja sytotoksiset lääkkeet sen suorittamiseksi.
DE3676248D1 (de) Ubidecarenon enthaltende arzneimittel.
FI895681A0 (fi) Farmaceutisk komposition foer systemisk transdermal tillfoersel.
DE3787377D1 (de) Eindringungserhöhende mittel zur transdermalen verabreichung systemischer mittel.
DE3576276D1 (de) Phenothiazine enthaltende arzneimittel.
FI813422A7 (fi) 1-Karboksi-atsa-alkanoyyli- indoliini- karboksyylihappoja, menetelmiä niiden valmistamiseksi, näitä yhdisteitsisältäviä farmaseuttisia valmisteita ja niiden terapeuttinen käyttö.
DK79889A (da) Flerlagsplaster til transdermal laegemiddeladministration
DK208784A (da) Farmaceutisk produkt til kontrolleret afgivelse af aktive stoffer til huden
DZ327A1 (fr) Imino diacides substitutes, leur préparation e composition pharmaceutiques les contenant.
DK173081A (da) Farmaceutisk produkt til oral administration indeholdende cytidindiphosphocholin
FI852658A7 (fi) Farmaseuttiset aineet.
MA19907A1 (fr) Procede de preparation de derives de la thiatriazine et utilisation de ceux-ci dans des compositions pharmaceutiques.
OA06776A (fr) Procédé de préparations pharmaceutiques.
MA19893A1 (fr) Procede de preparation de derives de sulfamoylbenzophenone et utilisation de ceux-ci dans des compositions pharmaceutiques.
FR2513994B1 (fr) Tripeptides anorexigenes, procede pour leur preparation et compositions pharmaceutiques les contenant
FI862493A0 (fi) Fysiologiska medel foer effektivering av transdermal administration av laekemedel.
FI821896A7 (fi) 4-amino-bentsyyliamiini-johdannaiset, menettely niiden valmistamiseksi ja niiden käyttö farmaseuttisina aineaineina.